BR0010366A - Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia - Google Patents

Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia

Info

Publication number
BR0010366A
BR0010366A BR0010366-7A BR0010366A BR0010366A BR 0010366 A BR0010366 A BR 0010366A BR 0010366 A BR0010366 A BR 0010366A BR 0010366 A BR0010366 A BR 0010366A
Authority
BR
Brazil
Prior art keywords
compound
carbon atoms
optionally
pyrimidinyl
pyridinyl
Prior art date
Application number
BR0010366-7A
Other languages
English (en)
Inventor
Keith Hopkinson Gibson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0010366A publication Critical patent/BR0010366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE PREPARAR UM COMPOSTO, E, COMPOSTO PARA USO EM TERAPIA". Um composto de fórmula (I) ou um seu sal farmaceuticamente aceitável, para uso na manufatura de um medicamento para inibição de MEK em um mamífero com uma doença mediada por MEK, em que: n é 0-1; Y é selecionado de -NH-, -O-, -S- ou -NR^ 7^, em que R^ 7^ é alquila de 1-6 átomos de carbono, R^ 6^ é cicloalquila de 3 a 7 átomos de carbono, que pode ser opcionalmente substituída por um ou mais grupos alquila de 1 a 6 átomos de carbono; ou é um anel piridinila, pirimidinila ou fenila; em que o anel piridinila, pirimidinila ou fenila podem ser substituídos por um, dois ou três substituintes especificados; ou R^ 6^ é um grupo -R^ 8^-X-R^ 9^, em que R^ 8^ é uma cicloalquila divalente de 3 a 7 átomos de carbono, que pode ser opcionalmente substituída ainda por um ou mais grupos alquila de 1 a 6 átomos de carbono; ou é opcionalmente um anel piridinila, pirimidinila ou fenila; em que o anel piridinila, pirimidinila ou fenila pode ser opcionalmente substituído ainda por um ou mais substituintes especificados, X é selecionado de CH~ 2~, -NH-, -O-, -S- ou -NR^ 5^, em que R^ 5^ é alquila de 1-6 átomos de carbono e R^ 9^ é um grupo (CH~ 2~)~ m~R^ 10^ em que m é 0, ou um número inteiro de 1-3 e R^ 10^ é um anel arila opcionalmente substituída ou cicloalquila opcionalmente substituída de até 10 átomos de carbono, ou R^ 10^ é um anel heterocíclico contendo 1 ou 2 átomos de oxigênio e, opcionalmente, um ou mais substituintes; e R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são, cada um independentemente, selecionados de hidrogênio ou vários grupos orgânicos especificados. Os novos compostos são também descritos e reivindicados.
BR0010366-7A 1999-05-08 2000-05-03 Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia BR0010366A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910580.1A GB9910580D0 (en) 1999-05-08 1999-05-08 Chemical compounds
PCT/GB2000/001698 WO2000068199A1 (en) 1999-05-08 2000-05-03 Quinoline derivatives as inhibitors of mek enzymes

Publications (1)

Publication Number Publication Date
BR0010366A true BR0010366A (pt) 2002-02-13

Family

ID=10852989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010366-7A BR0010366A (pt) 1999-05-08 2000-05-03 Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia

Country Status (16)

Country Link
US (1) US6638945B1 (pt)
EP (1) EP1178965B1 (pt)
JP (1) JP2002544194A (pt)
KR (1) KR20020000803A (pt)
CN (1) CN1350524A (pt)
AT (1) ATE250582T1 (pt)
AU (1) AU4589200A (pt)
BR (1) BR0010366A (pt)
CA (1) CA2371469A1 (pt)
DE (1) DE60005504T2 (pt)
GB (1) GB9910580D0 (pt)
IL (1) IL146319A0 (pt)
NO (1) NO20015447L (pt)
TR (1) TR200103185T2 (pt)
WO (1) WO2000068199A1 (pt)
ZA (1) ZA200108969B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365796A2 (en) 2000-09-01 2003-12-03 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
US7067532B2 (en) * 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
EP1337513A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JPWO2007132867A1 (ja) 2006-05-15 2009-09-24 杉本　芳一 癌の予防及び治療剤
CN101679357A (zh) * 2007-05-09 2010-03-24 辉瑞大药厂 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN106220560A (zh) * 2016-07-27 2016-12-14 华侨大学 一种多取代喹啉衍生物的制备方法
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
KR20230081932A (ko) 2021-11-30 2023-06-08 주식회사 메타뷰 실내 위치 측위 정보를 모니터링하는 고온환경 스마트 팩토리 안전관리 시스템 및 그 방법
KR102557537B1 (ko) 2022-08-25 2023-07-20 김형미 개선된 통신 방식을 활용한 스마트 도어 제어 방법, 장치 및 시스템
KR102498884B1 (ko) 2022-11-04 2023-02-10 주식회사 레딕스 현장 작업자와 화물차 기사의 안전관리를 위한 안전관리 시스템

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (pt) 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2114727C (en) 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
BR9810385A (pt) 1997-07-01 2000-09-05 Warner Lambert Co Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
IL142092A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
ATE255575T1 (de) 1998-09-29 2003-12-15 Wyeth Corp Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren

Also Published As

Publication number Publication date
NO20015447L (no) 2001-12-12
US6638945B1 (en) 2003-10-28
CN1350524A (zh) 2002-05-22
JP2002544194A (ja) 2002-12-24
TR200103185T2 (tr) 2002-05-21
AU4589200A (en) 2000-11-21
ZA200108969B (en) 2003-01-30
ATE250582T1 (de) 2003-10-15
NO20015447D0 (no) 2001-11-07
DE60005504T2 (de) 2004-06-24
EP1178965A1 (en) 2002-02-13
KR20020000803A (ko) 2002-01-05
DE60005504D1 (de) 2003-10-30
IL146319A0 (en) 2002-07-25
EP1178965B1 (en) 2003-09-24
CA2371469A1 (en) 2000-11-16
GB9910580D0 (en) 1999-07-07
WO2000068199A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
BR0010324A (pt) Composto, composição farmacêutica, e, método de preparação de um composto
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
GB9910577D0 (en) Chemical compounds
NO914960L (no) Medikamenter for canserterapi med antihistaminegenskaper
NO163855C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arylcyklobutylalkylaminer.
AU581324B2 (en) Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
ATE34753T1 (de) Derivate von pristinamycin iib, deren herstellung und deren pharmazeutische zusammensetzungen.
NO890440L (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
IE832109L (en) 1-arylcyclobutylalkylamine compounds
PT89082A (pt) Processo para a preparacao de novos derivados n-(23-vinblastinoilicos)do acido 1-amino-metilfosfonico
DE69409734D1 (de) Neue Derivate des 2-(1H)-Chinolinones, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
ES2084120T3 (es) Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina.
SE8800863L (sv) 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
SE8000699L (sv) Nya kinazolinderivat jemte sett for deras framstellning och farmaceutiska beredningar innehallande dem
DE69301639D1 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung
ATE67197T1 (de) Thiadiazinon-derivate.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007.